ProdigEye
AI clinical decision support for anterior-segment eye condition analysis from images.
Company Overview
Snapshot
Founded in February 2026 by Ron Ritter and Dr. Moshe Fisher, ProdigEye operates with 1–10 employees. The company is currently in the Pre-Funding stage, developing its AI-based clinical decision support platform.
Business overview
ProdigEye is a Health Tech & Life Sciences company specializing in Digital Healthcare, specifically Medical Decision Support. The company develops an AI-based clinical decision support platform for ophthalmology, focusing on anterior segment conditions. This system analyzes eye images to assist licensed clinicians in decision-making, with outputs intended for review by qualified practitioners rather than autonomous diagnosis. ProdigEye is developing its product as Software as a Medical Device (SaMD) and is currently in clinical validation and regulatory submission stages.
Log in to access full profile ›Company Intelligence Q&A
- What is ProdigEye's primary focus?
- ProdigEye focuses on developing an AI-based clinical decision support platform for ophthalmology, specifically for analyzing anterior segment eye conditions from images.
- When was ProdigEye founded?
- ProdigEye was founded in February 2026.
- Who are the founders of ProdigEye?
- ProdigEye was founded by Ron Ritter, who serves as Co-Founder & CEO, and Dr. Moshe Fisher, Co-Founder & Chief Medical Officer.
- What is the current development stage of ProdigEye's product?
- ProdigEye's product is currently in clinical validation and regulatory submission stages, being developed as Software as a Medical Device (SaMD).
- What is ProdigEye's business model?
- ProdigEye operates on a B2B business model.